# Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145

> **NCT06063343** · PHASE1 · COMPLETED · sponsor: **Novakand Pharma AB** · enrollment: 50 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** KAND145
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06063343
- **Lead sponsor:** Novakand Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-09
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063343, "Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06063343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*